Trial · NCT07457775
Liposomal Irinotecan in Combination With Temozolomide and Bevacizumab in Patients With Advanced STS
NCT07457775, Phase 2, Not yet recruiting, Second Affiliated Hospital, Zhejiang University, School of Medicine
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Liposomal Irinotecan in Combination With Temozolomide and Bevacizumab in Patients With Advanced STS. Trials, record NCT07457775. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07457775
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Liposomal Irinotecan in Combination With Temozolomide and Bevacizumab in Patients With Advanced STS
- NCT number
- NCT07457775
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 24 participants, estimated
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Conditions
- Soft Tissue Sarcoma (Excluding GIST)
- Interventions
- Irinotecan Hydrochloride Liposome Injection(II) combined with temozolomide and bevacizuma
- First posted
- 2026-03-09
- Last updated
- 2026-03-09
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free survival (PFS) | through study completion， assessed up to 24 months | Progression-free survival (PFS) is a measure used in clinical trials and medical research to evaluate the effectiveness of treatments, especially in oncology. It refers to the length of time during and after treatment that a patient lives with a disease without it getting worse. In other words, PFS is the duration from the start of treatment until the disease progresses or until the patient dies from any caus，whichever came first, assessed up to 24 months |
| Primary | Safety-Adverse events (AE) | through study completion，assessed up to 24 months | Adverse events (AE)/serious adverse events (SAE) (judged based on NCI-CTCAE 5.0), etc. |
| Secondary | Objective response rate (ORR) | through study completion, an average of 1 year | From the date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months |
| Secondary | 12-week PFS rate | 12 weeks | the percentage of patients who remain progression-free after 12 weeks treatment |
| Secondary | overall survival | through study completion, an average of 2 years | From the date of enrollment until the date of death from any cause or the end of the study, whichever came first, assessed up to 24 months |
| Secondary | Disease Control Rate (DCR） | through study completion, an average of 1 year | From the date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months |
| Secondary | Duration of remission (DoR） | through study completion, an average of 1 year | From the date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07457775
GET https://conductscience.org/api/trials/v1/NCT07457775/registered